UPDATE: HSBC Upgrades Qiagen N.V. to Neutral

In a report issued Tuesday May 13th, HSBC upgraded the rating on Qiagen QGEN from Underweight to Neutral with a target price of €17.00. HSBC analyst Jan Keppeler anticipates Qiagen's better research budget funding should help the company hit the 2014 4-5 percent sales growth target. While Keppeler does not see Qiagen as a “bargain,” she does see the risk much more limited than previously anticipated. On the NASDAQ, shares of Qiagen last traded at $22.39, down about 0.5 percent despite the HSBC upgrade.